Evidence map›Paper›PMID 37897330›Full record

ArticleLeukemia & lymphoma2023

Understanding treatment decisions for Hodgkin lymphoma: a qualitative study.

Anita J Kumar, Laurie K Pearson, John B Wong, Jonathan W Friedberg, Susan K Parsons, Amy M LeClair

Open access · greenAbstract read
In one paragraph

Article in Leukemia & lymphoma, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 66% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Anita J KumarTufts Medical Center Institute of Clinical Research & Health Policy Studies, Boston, MA, USA.ORCID 0000-0002-8704-0296
Laurie K PearsonTufts Medical Center Institute of Clinical Research & Health Policy Studies, Boston, MA, USA.
John B WongTufts Medical Center, Boston, MA, USA.
Jonathan W FriedbergThe Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA.
Susan K ParsonsTufts Medical Center, Boston, MA, USA.
Amy M LeClairTufts Medical Center Institute of Clinical Research & Health Policy Studies, Boston, MA, USA.
Tufts Medical Center · USUniversity of Rochester · US

Funding

Tufts Clinical and Translational Science Institute (Pilot Supplement)UL1TR002544 · NCATS · TUFTS UNIVERSITY BOSTON · PI SELKER, HARRY P. · 2018 to 2022
$50.2M
Tufts BIRCWH ProgramK12HD092535 · NICHD · TUFTS UNIVERSITY BOSTON · PI FREUND, KAREN, JAFFE, IRIS Z · 2017 to 2023
$4.3M
CTSA Graduate ProgramTL1TR002546 · NCATS · TUFTS UNIVERSITY BOSTON · PI KENT, DAVID M · 2018 to 2022
$4.2M
NCATS NIH HHS TL1 TR002546NCATS NIH HHS UL1 TR002544NICHD NIH HHS K12 HD092535
6 · The paper itself

Abstract

Hodgkin lymphoma (HL) affects older and younger patients and includes multiple options for initial treatment. We sought to examine the decision processes of practicing oncologists caring for patients with newly diagnosed HL. Through semi-structured interviews, we explored their perspectives about treatment decisions. We completed thematic analysis using the Anderson Behavioral Model of Health Services framework to identify factors associated with initial decisions. We completed 22 interviews, grouping findings into contextual factors, individual characteristics, and physician preferences. Paternalism was widely cited, along with collaboration between community and academic colleagues. Participants used sequential therapy but not geriatric assessment in care for older patients. Physicians had varied responses about use of frontline brentuximab vedotin (Bv)-based therapy based on perceptions about benefit versus toxicity. Our work suggests a need to further understand the heterogeneity of clinical practices, especially in the post-approval setting of new therapies.

Indexed as

Hodgkin DiseaseImmunoconjugatesOncologistsBrentuximab VedotinHumansNeoplasm Recurrence, LocalBrentuximab VedotinImmunoconjugatescancer care deliveryLymphoma and Hodgkin diseaseneoplasiaqualitative research

Identifiers

PMID37897330
PMCPMC12851507
OpenAlexW4388007321

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.